Vaxil Bio (TSXV:VXL) EBIT : C$-0.26 Mil (TTM As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Vaxil Bio EBIT?

Vaxil Bio's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was C$0.03 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.26 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vaxil Bio's annualized ROC % for the quarter that ended in Dec. 2023 was %. Vaxil Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vaxil Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -59.95%.

Vaxil Bio EBIT Historical Data

The historical data trend for Vaxil Bio's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxil Bio EBIT Chart

Vaxil Bio Annual Data

Trend

May14

May15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-1.14

-1.35

-0.99

-0.58

-0.26

Vaxil Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-0.17	-0.13	-0.13	-0.03	0.03

Competitive Comparison of Vaxil Bio's EBIT

For the Biotechnology subindustry, Vaxil Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxil Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxil Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vaxil Bio's EV-to-EBIT falls into.

Vaxil Bio EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.26 Mil.

Vaxil Bio (TSXV:VXL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vaxil Bio's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	0.104 * ( 1 - 0% )	/	( (0	+	0)	/ 2 )
=	0.104	/	0
=	%

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.05	-	0.19	-	( 1.009	-	max(0, 0.19	-	1.05	+	1.009	))
=	0

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.976	-	0.085	-	( 0.938	-	max(0, 0.085	-	0.976	+	0.938	))
=	0

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Vaxil Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	0.104	/	( ( (0 + max(-0.149, 0))	+	(0 + max(-0.066, 0)) )	/	2 )
=	0.104	/	( ( 0	+	0 )	/	2 )
=	0.104	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.041	+	0	+	2.2204460492503E-16)	-	(0.19	+	0	+	0)
=	-0.149

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.019)	-	(0.085	+	0	+	0)
=	-0.066

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vaxil Bio's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-0.259	/	0.432
	=	-59.95 %

Vaxil Bio EBIT Related Terms

Thank you for viewing the detailed overview of Vaxil Bio's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxil Bio (TSXV:VXL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxil Bio Ltd (TSXV:VXL) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

VXLLF:USA

Address

C/O Kira Lynn, Bennet Jones LLP, 3400 One First Canadian Place, Toronto, ON, CAN, M5X 1A4

Website

https://www.vaxil-bio.com

Vaxil Bio Ltd is an Israeli immunotherapy biotech company focused on a novel drug discovery and development platform based on Signal Peptides which the company deploys to fight infectious diseases and cancer.

Vaxil Bio (TSXV:VXL) Headlines

No Headlines